問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Digestive System Department

Division of General Internal Medicine

Division of Hematology & Oncology

China Medical University Hospital
Taipei Venterans General Hospital Taoyuan Branch

Division of Hematology & Oncology

更新時間：2023-09-19

許劭榮Hsu, Shao-Jung
  • Principal Investigator
  • Clinical Trial Experience (year) -8 years -4 個月

Recruiting Trial

33Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

許劭榮

List

42Cases

2025-03-31 - 2028-05-06

Phase I

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Recruiting2Sites

2025-07-15 - 2029-11-13

Phase II/III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2025-11-11 - 2030-12-31

Phase II/III

Active
A Phase 2b/3, Randomized, Double-Blind Study to Investigate the Efficacy, Safety, and Tolerability of Ponsegromab (PF-06946860) Compared With Placebo Both With Background First-Line Chemotherapy in Adult Participants With Cachexia and Metastatic Pancreatic Ductal Adenocarcinoma

  • Condition/Disease

    Metastatic Pancreatic Ductal Adenocarcinoma

  • Test Drug

    注射劑

Participate Sites
5Sites

Not yet recruiting5Sites

2020-06-26 - 2026-12-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-11-01 - 2027-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-07-01 - 2028-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-10-01 - 2027-11-01

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2026-04-01 - 2031-10-31

Phase II/III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2019-10-24 - 2021-03-08

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated1Sites

2021-10-01 - 2027-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting16Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB